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The 6
th European Lupus Meeting was held at the Royal College of Physicians of 
London and was attended by 450 delegates. The conference brought together leading 
speakers from Europe and North America who reviewed current knowledge and 
exciting new developments in both clinical and basic science aspects of systemic 
lupus erythematosus. This review summarises the major points covered in each 
session. The conference began with an evening of entertainment, including a live performance 
by the singer Dido who also spoke about her experiences as a relative of a patient with 
lupus.  Her appearance had been a well-kept secret until the opening ceremony and 
was complemented by Mitchell Dalton’s guitar solo and classical music from the 
Florilegium quartet. The evening’s proceedings started with Sir Peter Lachmann’s 
historical, geographical and scientific tour of lupus. It finished with an iconoclastic 
poem by Anisur Rahman (“The Appropriate Management of SLE on the Planet Mars” 
– currently in press in Rheumatology) and a 60’s style guitar band styled “Lupus Dave 
and the Davettes” featuring David Isenberg on lead vocals (don’t give up your day job 
yet David!). 
 
The meeting was a sell-out with 450 delegates. It was structured as parallel clinical 
and basic science sessions throughout apart from one plenary session. This review 
will describe the main points outlined in each session. 
 
Clinical Sessions 
 
Lupus and the kidney.  
 
Peter Schur pointed out that there were only some twenty-five randomised controlled 
trials in the literature of lupus nephritis (1) and even in those that have been 
performed there are serious problems of definitions of disease features and outcomes 
and problems of quality control, particularly with regard to renal histological findings. 
Jo Adu set out the thesis that tubulo-interstitial damage, which determines the extent 
of long-term renal impairment, is the sequela of glomerular injury, hypertension and hypertrophy, leading to proteinuria and ischaemia, both of which cause progressive 
interstitial fibrosis and tubular atrophy. In support of this hypothesis, macrophages are 
found in high density in areas of tubular damage where the monocyte chemoattractant 
protein MCP-1 is also highly expressed. Urinary MCP-1 levels correlate inversely 
with renal survival and a renal damage index correlates better with outcome than the 
WHO class of lupus nephritis (2). Therapies that reduce proteinuria (e.g. ACE 
inhibitors) and macrophage infiltration are likely to improve renal outcome. Harry 
Moutsopoulos reviewed antiphospholipid syndrome (APS) nephropathy in which 
patients typically are hypertensive, and may have chronic renal failure, mild 
proteinuria and intermittent haematuria (3). The renal arterial pathology comprises 
both fibrotic and thrombo-occlusive features, which can also be seen in other 
conditions such as hypertension, renal artery stenosis, scleroderma etc. In SLE these 
features are seen most commonly in patients with the APS but are also common in 
patients with antiphospholipid antibodies (aPL) alone (although a third of these will 
progress to APS) and occasionally in those without aPL. Presence of thrombo-
occlusive features is unrelated to WHO class and raises the question of whether these 
patients should be on prophylactic aspirin or warfarin. Finally Jo Berden finished the 
session with a review of end-stage renal failure in SLE (predictors of which are 
greater renal impairment, nephrotic syndrome, persistent disease activity, 
hypertension, WHO class III or IV, male sex, ethnicity) and of dialysis (no preference 
for haemodialysis or peritoneal dialysis, no excess mortality, beneficial effects of 
dialysis on disease activity) and transplantation. His unit has an extensive pre-
transplant assessment programme screening for cardiovascular disease, the APS, 
osteoporosis and autoreactive lymphocytes. Living donor transplantation has the best 
outcome and there is no worsening of outcome in SLE versus non-SLE patients. For immunosuppression they use a variety of agents for induction (Cyclosporin A, 
tacrolimus, mycophenolate mofetil (MMF), prednisolone) but favour MMF or 
azathioprine plus one other of the induction agents for maintenance therapy as these 
have less adverse effects on blood pressure or lipid/diabetic profiles. The recurrence 
rate of lupus nephritis post transplantation is low. 
 
Lupus and Atherosclerosis 
 
Ian Bruce reviewed the literature demonstrating that SLE patients develop earlier 
atherosclerotic cardiovascular disease than the general population and this is the 
major cause of excess late mortality in patients with SLE (4). Corticosteroid use may 
contribute to this and patients with the APS are at much higher risk. Even accounting 
for conventional risk factors, which themselves may be commoner in SLE patients, 
there is still an unexplained excess risk of 5-15 times the general population for 
cardiovascular events. He finished by asking whether statins and hydroxychloroquine 
will reduce this risk – clinical trials are needed. Jose Delgado-Alves described the 
pathway by which oxidation of low density lipoproteins (LDL) activates monocytes 
that develop into foam cells leading to atherosclerosis and thrombosis. This process is 
moderated by high density lipoproteins (HDLs) and the enzyme paraoxonase. He set 
out the evidence to support the hypothesis that, in patients with SLE,  anti-HDL 
antibodies and/or aPL interfere with these protective mechanisms (5). Susan Manzi 
described some of the non-invasive techniques that have been used to quantify the 
increased frequency of atherosclerotic lesions in SLE patients including thallium/dual 
isotope scans, electron beam CT (which can pick up calcification of the coronary 
arteries), intracoronary ultrasound (which can identify 20-25% stenosis compared with the 45% stenosis required before they can be identified by conventional 
angiography), endothelial function tests and carotid ultrasound to measure plaque 
thickness (6). Carotid ultrasound in particular may be a useful predictor of future 
events and for the assessment of progression of atherosclerosis. Finally David 
D’Cruz went through approaches to the reduction of conventional risk factors. He 
pointed out that angiotensin receptor blockers do not prevent myocardial infarctions 
and may not be interchangeable with ACE inhibitors. Hormone replacement therapy 
should be avoided in anticardiolipin antibody (aCL) positive patients. He raised 
cautions over the use of COX-2 specific anti-inflammatories in patients with SLE and 
posed the question whether all SLE patients should be taking low dose aspirin. He 
finished by emphasising the importance of good oral hygiene to reduce periodontal 
disease, which has been linked with an increased cardiovascular risk. 
 
Themed Abstract Session (Lupus. Vol 14(3):216-218) 
 
This session started with two presentations on the epidemiology of SLE, one 
worldwide (Danchenko et al, abstract OP6) and one on the effects of ethnicity in the 
UK (Patel et al, abstract OP7). McHenry et al (abstract OP8) presented data on the 
increased prevalence of cervical smear abnormalities in patients with SLE. Katz et al 
(abstract OP9) presented data that patients with SLE have particular difficulty 
maintaining ‘discretionary’, mainly leisure activities such as entertainment, sports, 
hobbies, travel etc. and that this correlated with depression scores. The same group 
(Yelin et al, abstract OP10) then presented data showing that SLE patients had more 
work stops and starts than controls but overall those in employment were able to work 
less than controls during the study period.  
Lupus and the Skin, Lungs and Abdomen 
 
Using the comprehensive database of clinical information available in her unit at 
Johns Hopkins, Michelle Petri described lupus chest disease. Pleurisy is commoner 
in African-Americans than in other ethnic groups and can often be treated with anti-
malarials and /or NSAIDs. More severe cases may require short courses of 
corticosteroids but pleurectomy and pleurodesis are rarely needed. Rare 
manifestations of SLE include lupus pneumonitis, pulmonary haemorrhage (seen in 
2% of the Hopkins cohort), shrinking lung syndrome (<1%) and diffuse interstitial 
lung disease (in 3%). Pulmonary hypertension in SLE is usually mild but may be 
increasing in prevalence as the population of patients with SLE becomes older.  
Peter Maddison described the spectrum of lupus skin disease from chronic cutaneous 
forms to skin involvement in acute systemic disease. It is important to stress the clear 
link between exposure to sunlight and cutaneous SLE and to advise patients to take 
adequate measures to protect themselves from the sun. A multi-disciplinary approach 
involving rheumatologists, dermatologists and nurses, incorporating a strong 
emphasis on self-management is often preferable. 
Anisur Rahman explained that, while abdominal symptoms are commonly reported 
by patients with SLE, these symptoms are not usually due to the disease itself. Mouth 
ulcers are frequently painless and estimates of their prevalence vary. Patients with 
SLE and an acute abdomen may have mesenteric vasculitis. The rarity of this 
complication means that evidence about it comes from retrospective studies, which 
are difficult to compare. Ultrasound scan and angiography are often uninformative but 
computed tomography may be helpful. However, in many cases a laparotomy may be needed to make the diagnosis. Some authors report a high mortality, especially from 
perforation, but other report good outcomes with courses of intravenous 
corticosteroids. 
 
Outcomes in Lupus  
 
Murray Urowitz presented data on the huge improvement in survival rates for SLE 
over the past 30 years. This has led to an increase in late morbidity, at least in part due 
to corticosteroid use. Avascular necrosis is one important form of late morbidity 
related to corticosteroids. Neurocognitive dysfunction, atherosclerotic cardiovascular 
disease and osteoporosis are also common forms of late morbidity. Ann Clarke 
presented data from the Tri-nation Study on resource utilisation by patients with SLE 
in the USA, UK and Canada which was generally higher in the USA than in the other 
countries (7). Clarissa Pilkington concluded the session with a review of paediatric 
SLE. Key features are that lupus in males is relatively more common (1:4) in children, 
and it often evolves from other conditions such as idiopathic thrombocytopenic 
purpura. Fatigue, haematological and central nervous system (CNS) involvement are 
common. Chronic active hepatitis is also more frequent as is the macrophage 
activation syndrome (seen only rarely in adults). Patients often lose long periods of 
school time with substantial consequences. Teenage compliance and the management 
of the whole family are important paediatric issues. 
 
Central Nervous System Lupus 
 John Hanly started by describing the work of the ad hoc American College of 
Rheumatology (ACR) committee on agreeing the definitions and components of 
neuropsychiatric (NP) lupus (8). In terms of markers, aCL are associated with a fall in 
cognitive function over a five-year period. It is unclear whether anti-ribosomal P 
antibodies are relevant to NP lupus. Measurements of blood-brain barrier function are 
impaired in a third of patients. Markers that may prove to be useful include CSF 
cytokine levels. Matrix metalloproteinase 9 is increased in CSF of patients with NP-
SLE and may correlate with MRI findings and markers of neuronal damage. Betty 
Diamond described her work on cognitive impairment induced by anti-N-methyl-D-
aspartate (NMDA) receptor antibody in mice. This followed an observation that a 
monoclonal anti-dsDNA antibody cross-reacted with an NMDA peptide. Injection of 
such an antibody with lipopolysaccharide (LPS) (to induce permeability of the blood-
brain barrier which is critical for the antibody to cause cerebral damage) caused 
cognitive impairment via preferential binding to the hippocampus i.e. an antibody 
mediated non-inflammatory model of cerebral lupus (9). John Axford described 
imaging techniques available for SLE including MR spectrometry and Diffusion 
Tensor Imaging. Dafna Gladman concluded the session with a review of therapy for 
CNS lupus ranging from symptomatic treatment to immunosuppression with 
cyclophosphamide. In some patients cognitive dysfunction can improve with 
corticosteroids and if the APS is present it is important to treat it by anticoagulation. 
 
Themed Abstract Session (Lupus. Vol 14(3):220-221) 
Ruiz-Iratorza et al (abstract OP16) presented a retrospective study suggesting that 
hydroxychloroquine may enhance survival in SLE. Fernandez et al (abstract OP17) 
presented data from the Lumina study on HRT use in SLE patients suggesting no clinically relevant adverse events and no differences among different ethnic groups. 
Guzman et al (abstract OP18) summarized their experience of Rituximab therapy and 
Willeke et al (abstract OP19) described their groups’ experience of improvement in 
11 patients treated with immunoadsorption therapy. Finally Brunner et al (abstract 
OP20) presented findings that the medication cost of treating childhood SLE is 18,000 
US dollars per annum compared to 4,000 US dollars per annum for adults with SLE. 
 
Plenary Session: Translational Research to Treatment 
 
Graham Hughes started this session on new therapies with an overview of therapy 
including treatment of cutaneous lupus with combinations of  hydroxychloroquine and 
mepacrine or low-dose thalidomide, and severe systemic lupus with pulsed 
cyclophosphamide, MMF or rituximab. Epratuzamab, a humanised anti-CD22 
monoclonal antibody, is in development and intravenous immunoglobulin (IVIg), 
stem-cell transplantation and plasmapheresis may all have a role in some patients. 
Josef Smolen reviewed his experience of using anti-tumour necrosis factor alpha 
(TNFα) therapy in six patients with SLE. Michael Ehrenstein described the potential 
role of statins as an immunomodulator in SLE with particular reference to the 
restoration of normal lipid raft responses following T cell activation (10). Betty 
Diamond presented data on the use of single dose CTLA-4 Ig interference on co-
stimulatory activity on inducing remission in a safety study of 26 patients treated so 
far. Joan Merrill firstly summarised the basic science of BlyS and related molecules 
and their receptors involved in macrophage – B cell interactions. Over-expression of 
BlyS is found in murine models of autoimmunity and in some patients with SLE. At 
least one anti-BlyS monoclonal antibody is in development. Secondly she described the use of anti-double stranded DNA (dsDNA) antibody binding peptides in murine 
lupus. A phase-1 study of one such peptide (TV4710, Teva Pharmaceuticals) has 
recently been completed. Finally David Isenberg described the University College 
London Hospitals experience with Rituximab using a regime of IV 
methylprednisolone 750mg and Rituximab 1g on day 1 and IV cyclophosphamide 
750mg on day 2. Patients have their full blood count checked on day 10 and the 
process repeated on days 14/15. Patients stopped their previous treatment. Infection 
has not been a major problem. Anti-dsDNA antibody levels fall markedly in 
responders and B cells return at a mean of 4 months. Relapse only occurs when the 
autoantibodies return. Improvement is seen across all components of the BILAG 
index (11). 
 
Biomarkers 
The four speakers in this session discussed the importance and clinical utility of 
different antibodies, which have been suggested as markers of activity in SLE. 
 
David Pisetsky discussed antibodies to dsDNA, which are the most widely used 
biomarkers in SLE. High levels of anti-dsDNA antibodies are almost specific to SLE 
and these levels correlate with disease activity in many (but not all) patients. These 
antibodies may be pathogenic by a number of different mechanisms including 
deposition of circulating immune complexes (IC), binding to an antigen (such as 
nucleosomes) deposited from the blood, direct binding to tissue antigens (such as 
laminin or alpha-actinin) and penetration of living cells. Bacterial DNA is 
immunogenic in healthy people whereas mammalian DNA is not. It is possible that 
the ability of patients with SLE to make antibodies against mammalian DNA arises from stimulation by antigens containing DNA, for example chromatin breakdown 
products from mammalian cells. 
 
The possibility that “anti-dsDNA” antibodies in SLE may actually be anti-nucleosome 
antibodies was mentioned by Dr Pisetsky, and discussed in greater detail by Sylviane 
Muller. It is important to distinguish anti-histone antibodies, which are not specific or 
sensitive for SLE, from anti-nucleosome antibodies, which are more specific – though 
this depends on the method used to prepare the nucleosomes. Anti-nucleosome 
antibodies appear earlier than anti-dsDNA in some murine models and can be induced 
in healthy mice by the injection of syngeneic apoptotic thymocytes. These facts 
support the increasingly widely accepted hypothesis that abnormal clearance of 
apoptotic cell debris is one of the earliest events in the pathogenesis of SLE. Epitopes 
on this apoptotic material act as immunogens for both T cells and B cells. The idea 
that peptides derived from histones could therefore be used as tolerogens to treat SLE 
has been tested by Datta’s group, who injected such a peptide into SNF1 mice and 
prolonged survival (12). Thus, a better understanding of the anti-nucleosome response 
in SLE may be crucial to the management of the disease in future. 
 
Cees Kallenberg discussed antibodies to complement component C1q (anti-C1q). 
Although these are not specific for SLE, they may have a predilection for cases of 
renal SLE. Two groups published studies suggesting that high anti-C1q are more 
closely associated with renal flares than with flares in other systems.  An autopsy 
study showed that anti-C1q antibodies seem to be present at higher levels in the 
kidneys of patients with lupus nephritis than in their blood, suggesting that they are 
sequestrated in the inflamed kidney. Anti-C1q may play a number of roles in lupus nephritis. Although injection of monoclonal anti-C1q antibodies alone did not lead to 
nephritis in healthy mice, these antibodies did enhance the renal damage caused by 
rabbit anti-mouse nephrotoxic antibodies. Anti-C1q antibodies may also interact with 
surface C1q on apoptotic cell debris, promoting clearance of these cells by a pro-
inflammatory route. However, the anti-C1q assay is not used in clinical practice as 
commonly as the anti-dsDNA assay, perhaps due to technical factors. 
 
Anti-ribosomal P antibodies have been a source of controversy for some years. Data 
relating to these antibodies were reviewed by Ellen Ginzler. Although the prevalence 
of anti-ribosomal P antibodies in patients with SLE is not more than 20% in most 
studies, it is higher (36-38%) in Chinese patients. Although some have argued that 
high levels of these antibodies correlate with the presence of NP lupus, most studies 
are small and the results are inconsistent. There is therefore no consensus to support 
the measurement of anti-ribosomal P as a biomarker in routine clinical practice. 
 
Basic Science Sessions 
 
Lupus – the Link to Apoptosis  
 
A striking association is found between distinct autoantibody profiles and clinically 
distinct autoimmune diseases despite the fact that the best defined autoantigens in 
various  systemic  autoimmune  diseases  are  generally  ubiquitously  expressed  in  all 
cells. This conundrum of specificity was addressed by Anthony Rosen. His group 
have examined disease-specific autoantigen expression in normal and myositis muscle 
(13). They found that myositis specific antigen expression (e.g. Jo-1) was increased in myositis  muscle  only.  Conversely,  the  expression  of  non-myositis  autoantigens  & 
non-autoantigens  was  not  increased  in  myositis  muscle.  Furthermore,  myositis 
specific autoantigen expression was highest in regenerating muscle cells which were 
prominent in the myositis patients. Thus, Dr Rosen thought that healthy muscle is 
unlikely  to  be  the  site  of  initial  immunologic  injury  and  perhaps  specific  antigen 
expression patterns in regenerating muscle cells shape the phenotype-specific immune 
response (13). 
 
Significant challenges exist to studying auto-antigen expression in lupus patients in 
the same way. In particular, which tissue should be studied and how best to access the 
relevant tissue at the relevant time? The search for the most relevant animal model led 
Dr Rosen and colleagues to study chronic graft versus host disease (GVHD) in DBF1 
mice. In this disease model they found some similarities with SLE; antibodies to poly-
ADP ribose polymerase (PARP) – found in approximately 20% of patients with SLE - 
frequently  occurred  in  the  parent-F1  GVHD  mice.  Furthermore,  female  mice  had 
much higher titres of autoantibodies and had worse disease compared to male mice. 
The  titres  of  PARP  antibodies  were  increased  in  male  mice  by  administration  of 
apoptotic splenocytes, but not live cells, after induction of GVHD. Thus, Dr Rosen’s 
conclusion was that development of autoimmunity in GVHD mice (as in patients with 
autoimmune  rheumatoid  disease)  requires  simultaneous  satisfaction  of  a  complex 
group of circumstances, which include presentation of appropriate autoantigen.  
 
The importance of defects in clearance of apoptotic cells in patients with SLE was 
reviewed  by  Martin  Herrmann.  He  described  how  apoptosis  is  usually  a  non-
inflammatory event with apoptotic cells stimulating antigen presenting cells (APCs) to  increase  the  release  of  interleukin  (IL)  10  and  produce  less  TNFα.  During 
apoptosis chromatin is degraded before the cells lose their membrane integrity. The 
cells  are  rapidly  engulfed  and  digested  by  phagocytes,  especially  macrophages. 
Tingible body macrophages (TBMs) are found in germinal centres (GC) of secondary 
lymphoid  organs.  These  TBMs  efficiently  remove  apoptotic  cells  thus  avoiding 
contact of nuclear remnants with the immune system. This in turn prevents production 
and affinity maturation of anti-nucleosome/anti-dsDNA antibodies. 
 
These mechanisms are defective in patients with SLE. In particular, work performed 
by Dr Herrmann’s group has shown that in a subgroup of patients with SLE, apoptotic 
cells accumulated in lymph node GCs and the number of TBMs was significantly 
reduced. Consequently, nuclear autoantigens bind to follicular dendritic cells (DCs) 
and may thus provide survival signals for autoreactive B cells (14). 
 
Furthermore, Dr Herrmann described how treatment of apoptotic cells with Annexin 
V  (AxV)  significantly  increases  the  humoral  response  against  these  cells  (15), by 
masking exposure of phosphatidylserine (PS) - a recognition signal for macrophages - 
on the outer cytoplasmic membrane  early in apoptosis. In addition, AxV delayed the 
clearance of apoptotic cells by macrophages but not DCs.  Thus exposure of PS serves 
as an anti-inflammatory and immunosuppressive signal which is opposed by AxV and 
may be important in the generation of autoimmunity. 
 
The ability of DCs and macrophages exposed to various activation stimuli as well as 
meals of apoptotic and necrotic cells to break tolerance in normal mice was discussed 
by Keith Elkon (16). His group has found that mice injected with DCs incubated with apoptotic cells or necrotic cells developed high levels of IgG autoantibodies including 
anti-dsDNA and aCL. Similar results were obtained using DCs cultured in medium 
alone. Mice injected with DCs which had undergone enhanced maturation with LPS 
developed significantly higher levels of total IgG, IgG anti-dsDNA and IgG aCL. In 
contrast, macrophages treated in the same way failed to induce generation of IgG 
antibodies.  Despite  high  serum  levels  of  IgG  anti-dsDNA  antibodies,  as  well  as 
prominent renal deposition of IgG in the kidneys, mice injected with DCs did not 
develop overt nephritis. This lack of clinical disease was thought to be explained by a 
marked skewing of autoantibodies towards the IgG1 isotype as opposed to the more 
pathogenic  IgG2a isotype. Thus, Dr Elkon concluded that mature DCs are able to 
break  tolerance  and  induce  autoantibodies  in  normal  mice  but  other  susceptibility 
factors are required to induce long lasting autoimmunity and clinical expression of 
disease (16). 
 
In the context of autoimmune disease, DC uptake of apoptotic cells in the presence of 
a  maturation  signal  breaks  tolerance  by  the  coordinate  engagement  of  Toll-like 
receptors (TLR), CD40 or activating Fcγ receptors. Dr Elkon reviewed evidence that 
immune complexes consisting of DNA and anti-dsDNA antibodies can activate DCs 
to produce high levels of inflammatory cytokines, such as interferon (IFN)α, involved 
in the pathogenesis of SLE. This process occurs relatively independently of TLR4, 
TLR9 (17) or MyD88 (18) signalling pathways. Furthermore, the entry of mammalian 
DNA into DCs is a potent inducer of type 1 IFN through a non TLR 9 route.  
 
In the final part of his talk Dr Elkon addressed the question of how apoptotic cells 
suppress immune responses. He presented data demonstrating that cell-cell contact with apoptotic cells is sufficient to induce profound inhibition of IL-12 production by 
activated macrophages, through interaction of PS on apoptotic cells with its receptor 
on macrophages. He also reported the identification of a novel zinc finger nuclear 
factor,  named  GC  binding  protein,  induced  by  phagocytosis  of  apoptotic  cells  by 
macrophages  or  by  treatment  with  PS,  which  selectively  inhibits  IL-12  gene 
transcription (19).  
 
Interferons, cytokines and lupus 
 
This session dealt with four of the cytokines which have been studied most 
extensively in SLE and which may offer the best hopes for therapeutic intervention. 
 
Lars Ronnblom discussed IFNα. Patients with SLE have high levels of IFNα, which 
correlate with disease activity. Cells expressing IFNα have been demonstrated in both 
inflamed and non-inflamed skin of patients with cutaneous SLE. Microarray studies to 
profile gene expression show that peripheral blood cells of patients with SLE tend to 
show upregulation of IFN induced genes. Dr Ronnblom outlined the theory that IC 
containing nuclear material from dying cells bind to IFN-producing cells via the 
FcγRIIa receptor. This triggers the production of IFNα, which itself promotes B cell 
maturation and antibody production, creating a positive feedback loop. The potential 
importance of IFNα in SLE was underlined by studies showing that knockout of 
interferon genes ameliorates disease in murine models of lupus. 
 
Genetic studies in Scandinavia looked for association of SLE with the presence of 44 
single nucleotide polymorphisms (SNPs) in 13 genes (20). There were strong associations with two genes involved in the interferon system – tyrosine kinase 2 and 
IFN regulating factor 5. It must be noted, however, that both genes are also involved 
in other cytokine pathways and there are more than 200 other genes related to the 
Type I IFN pathway. Any conclusions about the roles played by these genes in the 
pathogenesis of SLE remain speculative. 
 
Rizgar Mageed discussed TNFα, which  has a complex mode of action in SLE. 
Studies in NZB/W F1 mice showed that this cytokine ameliorates lupus-like disease 
in that model, and anti-TNFα drugs given to patients with rheumatoid arthritis can 
cause production of anti-dsDNA antibodies. In established SLE, however, there is 
evidence that TNFα is involved in causing tissue inflammation, and some groups 
advocate using anti-TNFα to treat patients with SLE. Professor Mageed’s group have 
studied the effect of TNFα and anti- TNFα on adult and neonatal NZB/W F1 mice. In 
the adult mice, as expected, administration of TNFα reduced the size of germinal 
centres and reduced levels of anti-dsDNA antibodies. In neonatal mice, the original 
hypothesis that TNFα might promote autoimmunity by interfering with thymic 
development of T cell tolerance was disproved. In fact, anti-TNFα given to neonatal 
mice leads to increased B cell proliferation, no effect on T cell proliferation at four 
weeks and increased levels of anti-dsDNA and anti-nucleosome antibodies. Anti-
TNFα therefore seems to promote autoimmunity in both adult and neonatal NZB/W 
F1 mice. 
 
Professor Mageed also described early results from studies using B cells from patients 
with SLE and raised the intriguing possibility of using targeted gene therapy to 
modulate TNFα function in lupus-affected tissues such as the kidney.  
Dominique Emilie discussed IL -6 and IL-10. IL-6 levels tend to be high in patients 
with SLE and are related to disease activity. Since activated B cells produce IL-6 and 
have IL-6 receptors, a positive feedback loop may operate. In NZB/W F1 mice, 
blocking IL-6 or the IL-6 receptor delays the onset of nephritis. 
 
IL-10 levels are also raised and correlate with disease activity in patients with SLE. 
IL-10 acts as a polyclonal activator of B cells. When peripheral blood mononuclear 
cells (PBMC) from patients with SLE are injected into severe combined 
immunodeficiency (SCID) mice, the amount of human IgG produced by those cells is 
reduced by the administration of anti-IL-10 to the recipient mice. Levels of 
autoantibodies produced by the human PBMC  are particularly sensitive to anti-IL-10. 
A pilot study in human SLE showed some reduction in disease activity following 
administration of a murine monoclonal anti-IL-10 antibody (21). Attempts to develop 
a humanised anti-IL-10 for further trials seem likely to follow.  
 
In NZB/W F1 mice, survival of peritoneal B lymphocytes is promoted by the 
chemokine SDF-1, and this effect is enhanced by IL-10. Administration of anti-SDF-1 
to NZB/W F1 mice reverses established nephritis.  In recent experiments, Koutouzov 
and colleagues used an adenoviral vector to administer murine IFNα cDNA to pre-
autoimmune NZB/WF1 mice (22). The recipient mice developed sustained high levels 
of serum IFNα.  These mice developed earlier glomerulonephritis with proteinuria 
and died earlier than control mice that received vector containing no cDNA or no 
vector at all. The effect was strain-specific such that BALB/c mice treated in the same 
way did not develop any similar disease.  
Complement and Lupus 
 
Inherited deficiencies in the complement system can predispose to the development of 
SLE. Gunnar Sturfelt described the hierarchical relationship of complement 
deficiency and SLE within the classical pathway as C1q/C1r/C1s > C4 > C2. In a 
cohort of 43 patients in Sweden with homozygous C2 deficiency, invasive infection is 
the most frequently observed manifestation (23/40), followed by cardiovascular 
disease (myocardial infarctions in 10 patients and stroke in six), followed by SLE in 
11 patients (23). None of these patients have antibodies to dsDNA, despite one patient 
developing lupus nephritis. Anti-C1q antibodies are present in 56% and 44% have 
aCL despite none developing the APS. In vitro, serum deficient in C1q or C2 results 
in reduced clearance of apoptotic cells, which is normalised after replenishing the 
deficient complement, suggesting a possible mechanism contributing to the eventual 
loss of tolerance to these autoantigens. 
 
The possibility of using levels of complement components as biomarkers in SLE was 
discussed. Low C1q as a biomarker of SLE has a very high specificity of 96% but the 
sensitivity is low at 20%, compared to low C3 or low C4, which both have higher 
sensitivities of 64% (24). Low levels of C1q are present in 50-80% of renal SLE 
flares, and tend to precede drops in C3 and C4 levels. Low C1q can predict 
histopathological outcome of lupus nephritis, as evidenced by a strong association 
with WHO Class III-IV. It was stressed that measurement of complement activation 
products may be valuable in terms of monitoring disease activity with serial measurements, rather than as a diagnostic tool. Urine C3d levels are increased in 
active lupus nephritis but this test has low specificity for SLE. 
 
The ‘waste-disposal’ hypothesis put forward by Mark Walport and colleagues 
proposes that defects in the clearance of dying apoptotic cells and / or IC may provide 
the source of persistent autoantigen driving the inflammatory process. Kevin Davies 
summarised evidence linking the role of defective mechanisms of IC clearance, 
complement and Fc receptors to the pathogenesis of SLE. In healthy people IC are 
opsonised by bound C3b allowing them to bind to erythrocyte-CR1 receptors 
clustered on the surface of red blood cells. The erythrocytes transport the IC to the 
hepatic phagocyte where they are removed via Fc binding. Erythocyte-CR1 is reduced 
in patients with SLE. Experiments using radiolabelled IC in the normal population 
have shown these IC are cleared into the liver and spleen equally. In patients with 
SLE however, 80% are cleared by the liver and 20% by the spleen. Furthermore, 
clearance into the liver is more rapid as is subsequent release of the complexes 
implying defective retention. IC clearance studied in one patient with C2 deficiency 
showed similar abnormal results in both the kinetics and localisation of IC clearance, 
with no uptake of IC in the spleen. These abnormalities were reversed with C2 
repletion. These experiments, among others, suggest that soluble IC cleared by Fc-
receptors are processed by the liver. This processing is defective with poor retention 
of these complexes, suggesting a possible link with Fc-R polymorphisms observed in 
SLE. Splenic uptake of IC however is complement-dependent.  
 
A dynamic flow system has been used to show that uptake of IC by mononuclear 
phagocytes is more efficient when the complexes are bound to erythrocytes in the fluid phase under physiological flow. Transfer may involve an adhesive interaction 
between erythrocytes bearing the IC and receptors of both Fc and complement on the 
phagocyte surface. FcγRIIa polymorphism influences binding of IgG2 containing IC, 
with a reduction of FcγRII demonstrated on phagocytes from patients with lupus (25). 
 
In keeping with the ‘waste-disposal’ theme, Marina Botto discussed the possible role 
of C1q in the defective clearance of apoptotic cells. Clinically C1q deficiency is 
closely associated with SLE. In one cohort studied 39 out of 42 patients with inherited 
C1q deficiency suffered from SLE. C1q knockout mice develop glomerulonephritis 
with the presence of glomerular apoptotic bodies. Experiments using both IgM and 
C1q deficient mice showed that uptake of apoptotic thymocytes by macrophages in 
vitro was normal only when normal levels of both C1q and IgM were present, 
suggesting that C1q binding to apoptotic bodies is mediated by IgM.  
 
Anti-C1q antibodies are strongly associated with the presence of lupus nephritis and 
accumulate in the nephritic kidney. Murine anti-C1q antibodies infused into mice 
naïve to these antibodies have no pathological effect. However if these mice are pre-
injected with antibodies to the glomerular basement membrane, anti-C1q antibodies 
cause significant albuminuria and enhanced histological renal damage. It thus seems 
that anti-C1q antibodies bind C1q in the kidney but only induce disease in the context 
of glomerular IC deposition (26).  Finally work investigating the possibility of 
manipulating levels of C1q in vivo was discussed. Patients with inherited C1q 
deficiency and SLE infused with fresh frozen plasma develop normal levels of C1q 
that lasts for only 48 hours, requiring re-treatment every two to three weeks. 
Irradiated C1q deficient mice reconstituted with wild-type bone marrow develop sustained presence of serum C1q detected up to 60 weeks post bone marrow 
transplantation. Could bone marrow transplantation be a possible therapeutic strategy 
in the treatment of SLE associated with genetic deficiency of the classical pathway 
components? 
 
Cell signalling defects  
 
Activation of B cells in autoimmunity may not always lead to a pathogenic outcome. 
Accumulating  evidence  for  the  existence  of  a  subset  of  B  cells  that  have  a 
suppressive/regulatory effect on the expansion/differentiation of autoreactive T cells 
was reviewed by Claudia Mauri. Previous work has shown that B cells treated with 
agonistic  anti-CD40  inhibit  Th1  cell  differentiation  and  prevent  murine  collagen 
induced arthritis by the production of IL-10 (27). 
 
To test whether regulatory B cells can be generated in other autoimmune diseases 
such  as  SLE,  Dr  Mauri  described  work  carried  out  by  her  group  in  lupus  prone 
MRL/lpr/lpr  mice.  Purified  B  cells  from  these  mice  at  9-10  weeks  of  age  were 
transferred to recipient mice and did not delay the onset of proteinuria or confer any 
enhanced  survival.  However,  stimulation  of  the  B  cells  with  anti-CD40  prior  to 
transfer  delayed  the  onset  of  proteinuria  and  autoantibody  production.  This 
phenomenon  was  associated  with  a  switch  to  IgG1  antibody  production  from  the 
pathogenic IgG2a subtype, similar to that induced by mature DCs described by Dr 
Elkon. 
 The phenotype of these regulatory B cells was studied by analysing various markers 
which characterise subsets of B cells at different stages of maturation. Immature B 
cells  leave  the  bone  marrow  and  enter  the  spleen  where  they  differentiate  into 
transitional type 2 (T2) B cells that reside within the splenic follicle. Activation of 
specific  signalling  events  in  T2  B  cells  leads  to  their  further  differentiation  into 
follicular mature or marginal zone (MZ) B cells (28). Dr Mauri found T2/MZ like B 
cells,  generated  upon  anti-CD40  stimulation,  to  be  the  major  producers  of  anti-
inflammatory  regulatory  cytokines.  Furthermore,  transfer  of  T2/MZ  like  B  cells 
delayed the progression of spontaneous lupus-like disease in MRL/lpr/lpr mice as 
shown by reduced levels of proteinuria, IgG anti-DNA antibodies and nephritis. In 
addition, unlike other subsets of B cells in vivo, T2/MZ B cells induced a switch from 
IgG2a  to  IgG1  antibodies  and  in  vitro  efficiently  suppressed  the  proliferation  of 
activated T cells and Th1 differentiation. 
 
Elizabeth Jury described how the organisation of signalling molecules into discrete 
membrane  associated  microdomains,  called  lipid  rafts,  regulates  T  cell  activation 
pathways.  In  resting  T  cells,  lipid  rafts  -  detected by  Cholera  toxin  B  binding  to 
glycosphingolipid (GM1) – form a low proportion of the plasma membrane. T cell 
activation however, induces an increase in the proportion of the plasma membrane 
adopting a lipid raft conformation, measured by up-regulation of raft-associated GM1, 
and concentrates signalling molecules such as lymphocyte specific protein tyrosine 
kinase (LCK) to the immunological synapse.  
 
Studies  performed  by  Dr  Jury  have  shown  that  LCK  expression  is  significantly 
reduced in both raft and non-raft fractions in T cells isolated from patients with SLE. Furthermore,  this  reduction  is  associated  with  disease  activity  and  parallels  an 
increase in LCK ubiquitination independent of T cell activation (29). T cells freshly 
isolated from patients with SLE also express higher levels of raft associated GM1 
with an increased expression of co-localised CD45 and activated LCK compared to 
controls  (30).  Thus,  these  T  cells  are  “primed”  for  activation  and  respond  more 
readily to antigenic triggers than T cells from normal controls. 
 
Intriguingly, the well described immunomodulatory effects of statins may occur due 
to their ability to reverse lipid raft abnormalities in lupus T cells. Dr Jury explained 
how  atorvastatin  interferes  with  T  cell  activation  by:  -  depleting  membrane 
cholesterol; disrupting the integrity of lipid rafts; altering the membrane distribution 
of raft-associated signalling molecules; restoring LCK expression in SLE T cells; and 
reducing  LCK activation in SLE T cells. Thus, statins prevent the formation of a 
stable immunological synapse and T cell activation in addition to their cholesterol 
lowering properties (10).  
 
Syamal Datta described peptide therapy in lupus prone mice. Nucleosome derived 
peptide epitopes were administered subcutaneously in very low doses to these mice. 
These peptides induced tolerance by generating long-lasting regulatory T cells that 
suppressed the production of pathogenic autoantibodies and prolonged the life of the 
mice by delaying the onset of nephritis. Thus, the beneficial effects of the peptides 
outlasted their short half-life and generated long lasting regulatory T cells, without 
causing allergic/anaphylactic reactions or generalised immunosuppression (12).  
 Dr Datta reviewed a number of intrinsic T cell mechanisms that contribute to the 
breakdown of tolerance in lupus.  Up-regulation of CD40 ligand (CD40L) is found in 
T cells of lupus patients and occurs with suboptimal TCR stimulation. This CD40L 
up-regulation is associated with impaired phosphorylation of Cassitus B lymphoma 
oncogene (Cbl) b, an enzyme with several important functions: - down-regulation of 
critical kinases such as LCK; facilitation of endocytosis of T cell receptors (TCRs) 
after signalling; and targeting downstream signalling proteins. Consequently lupus T 
cells with impaired Cbl-b function show persistent activation of the mitogen activated 
protein kinase extracellular regulated kinase which renders them resistant to anergy. 
Impaired function and expression of Cbl-b could also explain alterations in receptor 
clustering and lipid raft aggregation in the immunological synapse of lupus T cells, 
described by  Dr  Jury.  Thus,  increased  expression  of  CD40L  mediates  abnormally 
prolonged costimulatory signals to autoantibody producing B cells and may allow 
APCs to present apoptotic autoantigens in an immunogenic fashion in SLE (31). 
 
In addition Dr Datta described a novel role of COX-2. A sustained up regulation of 
COX-2 and the anti-apoptotic molecule cellular Fas-associated death domain-like IL-
1β converting enzyme inhibitory protein (c-FLIP) has been found in T cells of 
patients with SLE compared to healthy controls. Recent work has shown that certain 
COX-2 inhibitors such as celecoxib and niflumic acid induced marked apoptosis of 
anergy-resistant lupus T cells by down-regulating c-FLIP. The same COX-2 inhibitors 
also blocked nucleosome-specific T-cell recognition and autoantibody-inducing help 
in lupus prone mice (31). This raises the question of whether these drugs may be used 
as a maintenance therapy to prevent relapse in young patients with lupus who are in 
remission and do not have any contra-indications to COX-2 therapy.  
Genetic abnormalities 
 
Ward Wakeland summarised complex work using different animal models to dissect 
out genetic pathways that modulate susceptibility to systemic autoimmunity. The 
NZM2410 lupus prone mouse crossed with a B6 lupus resistant strain has been used 
to produce three congenic strains each carrying lupus susceptibility genes called Sle1, 
Sle2 and Sle3 respectively. Sle1 mediates loss of immune tolerance, Sle2 B cell 
hyperactivity and Sle3 mediates dysregulation of T cells. However none of these mice 
develop a lupus related clinical syndrome. Reassembly of congenic intervals B6.Sle1, 
B6.Sle2 and B6.Sle3 producing bi and tri congenic strains indicate that Sle1 is key for 
the development of fatal lupus. The combination of Sle1 with Sle2 or Sle3 results in 
fatal systemic autoimmunity with variably penetrant glomerulonephritis. In contrast 
the combinations of Sle2 and Sle3 failed to mediate fatal disease (32). Fine mapping 
studies of the Sle1 gene revealed a cluster of four loci (Sle1a-Sle1d) within the 
B6.Sle1 congenic interval. Sle1b is the most relevant with regards to pathogenicity. 
Genomic characterisation of the Sle1b locus identifies a highly polymorphic cluster of 
SLAM/CD2 family genes in the middle of the Sle1b critical interval (33). Studies 
were presented demonstrating that the SLAM/CD2 family polymorphisms modulate 
the cytokine secretion profile of CD4
+ T cells, resulting in decreased IL-4 production 
and preferential IFN-γ production. 
 
The Sle3, Sle5 and Yaa alleles mediate disruption of the immune system. Producing bi 
congenic intervals of these strains with ANA positive, non-pathogenic B6.Sle1 strains 
leads to fatal autoimmune disease. Combining the bi congenic B6.Sle1/yaa with the autoimmune protective locus Sles1 however, results in a subsequent switch form of 
severe fatal autoimmunity to a non-autoimmune phenotype. The work presented 
underlines the diversity of regulatory genes in the immune system, with unfortunate 
combinations leading to imbalances in immune regulation. 
 
Marta Alarcon-Riquelme discussed evidence linking polymorphisms in the PDCD1 
gene to lupus susceptibility and presented work identifying possible functional 
mechanisms. The human PDCD1 gene has been shown to be located in the 
chromosomal region 2q37, a region that has been linked to SLE in multiplex Nordic 
SLE families. Sequencing the complete gene identified a number of SNPs and 
haplotypes constructed that were seen to preferentially transmit through to SLE-
affected individuals. The haplotype PD-1.3A was found in studies of ~1300 SLE 
Caucasian patients versus ~7000 controls to be associated with disease at a 
P<0.0000001 (odds ratio=1.7) (34).  
 
The PD1.3A haplotype may function to increase susceptibility in SLE as PD-1 is 
thought to control peripheral tolerance. PD1.3 is located in an intron which represents 
the binding site of the transcription factor RUNX/AML-1. The RUNX family of 
regulators (RUNX 1, 2 and 3) generally act as regulators of immunity and 
inflammation and can repress each other. RUNX1 and RUNX3 regulate CD8
+ T cell 
development in mice. RUNX1 binds to ‘wild-type’ PD1.3G but not to its allele  
PD1.3A. PD1 is expressed only in activated T cells in the PD1.3G haplotype  but in 
both activated and non-activated cells in  the PD1.3A haplotype, most likely due to 
consequent poor binding of regulatory proteins. This haplotype could therefore 
promote abnormal T cell function and hence promote autoimmunity.   
Tim Vyse gave a broader overview of SLE genetics and pointed out the difficulties  
associated with extrapolation of murine genetic observations to SLE disease in man. 
In mouse models such as the NZB/WF1 or MRL/lpr/lpr strains, the genes targeted 
induce disease with much less of an environmental effect. One must also consider that 
the mouse population is inbred with limited genetic variation, whereas the human 
population continues to undergo massive expansion. There are clearly common 
linkage regions in murine and human autoimmune disease, but orthologous regions 
are hard to establish. Detailed study of the region containing the high susceptibility 
murine Sle1b locus identifies the presence of IFN inducible genes Ifi202 and Ifi204. 
Analysis of the region 1q23 in the human chromosome reveals the presence of human 
Ifi genes encoding the transcriptional regulators MNDA, IFI-X, IFI-16 and AIM2. 
These are members of the HIN-200 family of proteins, expressed in haematopoietic 
and epithelial cells and up-regulated by type I and type II IFN. 
 
John Harley attempted to address how clinical variation in SLE may inform genetic 
studies. Data from a number of meta-analyses was presented stating the odds ratio for 
the association of SLE with variants of mannose-binding lectin gene (OR=1.4), TNFα 
genes (OR=4.6), PTPN22 (OR=1.6) and CR1 (OR=1.5). The Oklahoma Lupus 
Genetics Multiplex Pedigree Collection has an impressive  total number of 416 
pedigrees. Linkage to FcγRIIA is seen in 31 of the 127 African-American pedigrees. 
Mapping reveals a SNP in FcγRIIA causing a single point mutation arginine to 
histidine at position 131 (OR=1.35, p0.03) and a SNP at FcγRIIIA causing a 
phenylalanine to valine mutation at position 176 (OR=1.63, p0.002).   
 A possible relationship of SLE with Klinefelter’s syndrome was discussed. Out of a 
total of 213 men with SLE studied five were found to have Klinefelter’s syndrome 
through karyotype analysis. The expected prevalence of Klinefelter’s is 17:10,000 live 
births. Thus the actual observed rate of the extra X chromosome in men with SLE is 
in the region of 10 times that which one would expect, similar to the ratio of females 
to males with SLE. It would seem that the Y chromosome is irrelevant and the 
occurrence of SLE in patients with Turner’s syndrome (XO), though reported (one 
published case (35)) is extremely rare.  
 
In the final part of Dr Harley’s talk linkages to SLE by stratification using clinical 
features was discussed. Patients with anti-dsDNA antibodies exhibit linkages to 
19p13. A recent study by Sigurdsson et al (20) has identified two SNPs found in 
exploring 13 IFN responsive genes separately in Swedish, Icelandic and Finnish 
patients with SLE. SNPs were identified in the tyrosine kinase 2 (TYK2) gene at 
19p12.2 that displayed strong signals in joint analyses of linkage and association. 
TYK2 binds to the type I IFN receptor complex. 
 
 
Antigens and antibodies in lupus 
 
Bevra Hahn described the panoply of autoantigens which may be involved in SLE. 
Some of these are foreign antigens such as Epstein-Barr virus. Children with SLE are 
50 times more likely to be seropositive for EBV exposure than healthy children. Self-
antigens, however, have been more extensively studied in SLE. Many of these are 
proteins or nucleic acid/protein complexes found on apoptotic blebs and other subcellular particles released after apoptosis. Arbuckle’s study on stored blood from 
American military personnel showed that autoantibodies to these antigens may be 
present in the blood of patients with SLE years before they develop clinical features 
of the disease (36). Different autoantibodies may develop as the disease progresses 
and this may arise from epitope spreading, a process in which exposure to one 
autoantigen gradually leads to the production of antibodies to a range of related 
antigens. For example, an initial anti-nucleosome response may be followed by 
production of anti-dsDNA and anti-histone as well as anti-nucleosome antibodies. 
 
Some autoantigens may be important as targets in the disease process. These include 
alpha-actinin, identified by two separate groups as being a possible target in renal 
SLE. Antibodies that cross-react with DNA and NMDA bind the mouse hippocampus 
and may be involved in cerebral SLE. Antibodies which bind beta-2-glycoprotein I, 
prothrombin or thrombin are important in the APS. 
 
Autoantibodies may themselves act as autoantigens. Peptides from the VH regions of 
some human anti-dsDNA antibodies can stimulate T lymphocytes from patients with 
SLE to produce IFN-γ. T lymphocytes from healthy people are less likely to be 
stimulated by these peptides. 
 
Mark Shlomchik addressed the issue of how autoreactive B cells are activated in 
autoimmunity with reference to an elegant model using mice transgenic for a murine 
allotype-specific rheumatoid factor. In normal mice, the transgenic B cells are 
anergised, whereas on a lupus prone background the transgene is expressed. 
Expression is higher in mice that have the target allotype. In these mice, the autoreactive, rheumatoid factor positive B cells lie outside the germinal centres, and 
may escape from normal tolerance mechanisms. These autoreactive cells are 
stimulated when allotype positive anti-chromatin antibodies are administered to the 
transgenic mice. This response may be mediated by TLR9 reacting to chromatin/anti-
chromatin complexes. However, although knocking out the TLR9 gene in 
MRL/lpr/lpr mice (by cross-breeding with TLR9 knockout mice) reduces production 
of anti-dsDNA antibodies, these mice still develop glomerulonephritis. 
 
Thomas Dorner looked at the issue of B cell subsets in patients with SLE. His group, 
and others, have identified CD27 high early plasma cells as a population whose levels 
are raised in SLE and correlate with disease activity (37). Some of these cells express 
high levels of surface HLA-DR antigen and can migrate towards the bone marrow. 
The ICOS-ICOS ligand system may be important in the development of B cells in 
SLE. ICOS deficiency in humans leads to low B cell numbers and low IgG levels. In 
patients with SLE, T cell ICOS expression is high and ICOS-ligand on B cells is 
down-regulated, leading to the speculation that this pattern is due to recent T-B cell 
interactions, which may be important in disease pathogenesis. 
 
Conclusion 
 
The 6
th European Lupus Meeting was generally agreed to be a great success, with a 
broad range of subjects being discussed in detail. Interested readers who were unable 
to attend the conference itself will find more information in the references listed 
below. The 7
th European Lupus Meeting will be held in Amsterdam. 
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